Royal Bank Of Canada Citius Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 05, 2024	BUY	$0.6 - $0.9 $1,821 - $2,732	3,036 New	3,036 $2,000
Q1 2024 May 15, 2024	SELL	$0.6 - $0.9 $21,948 - $32,922	-36,581 Reduced 92.34%	3,036 $2,000
Q4 2023 Feb 14, 2024	BUY	$0.65 - $0.86 $12,711 - $16,818	19,556 Added 97.48%	39,617 $30,000
Q3 2023 Nov 14, 2023	BUY	$0.65 - $1.25 $4,932 - $9,485	7,588 Added 60.84%	20,061 $13,000
Q2 2023 Aug 14, 2023	BUY	$1.08 - $1.65 $13,470 - $20,580	12,473 New	12,473 $14,000
Q3 2022 Nov 14, 2022	BUY	$0.14 - $1.33 $9 - $90	68 New	68 $0
Q2 2022 Aug 15, 2022	SELL	$0.88 - $1.87 $6,698 - $14,234	-7,612 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.38 - $1.89 $21,627 - $29,620	-15,672 Reduced 67.31%	7,612 $14,000
Q4 2021 Feb 14, 2022	BUY	$1.51 - $2.2 $12,747 - $18,572	8,442 Added 56.88%	23,284 $36,000
Q3 2021 Nov 15, 2021	BUY	$1.74 - $2.6 $12,267 - $18,330	7,050 Added 90.48%	14,842 $30,000
Q2 2021 Aug 16, 2021	BUY	$1.51 - $4.23 $11,765 - $32,960	7,792 New	7,792 $27,000

23.7M

83.1K

32.1K

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $378M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.